ESTEVE CO-LEADS INTERNATIONAL CONSORTIUM FOR THE DEVELOPMENT OF MORE EFFICACIOUS THERAPIES FOR NEUROPATHIC PAIN
NGN-PET is a project launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry. ESTEVE, along with five other partners, is part of this project for the development of novel, more efficacious treatments for chronic pain of neuropathic origin.
Neuropathic pain affects 8.2% of the population and the efficacy of current treatments is limited, which results in 60% of patients being improperly treated. NGN-PET is a 6-partner consortium led by ESTEVE, supported by Grünenthal and coordinated by Axxam, that brings together experts from industry, SMEs and academia and that will focus on the study of neuronal and glial cells to discover novel, more efficacious treatments for neuropathic pain.
Specifically, the new approach of NGN-PET will investigate neuron-glial interactions in two models of neuropathic pain -induced by chemotherapy or trauma- to develop cellular systems that provide a translational platform and create human-predictive test systems that can be implemented in the drug discovery process.
With a duration of 3 years, the NGN-PET project is supported by over 3 million euros from IMI2 and industry partners in direct and in-kind contributions
Download the complete news in pdf
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more